Agenus Q1 Revenue Misses at $33.7M; Net Income $39.2M Turns Positive
AGEN•Agenus reported Q1 revenue of $33.7M, up from $24.1M, but fell short of the $129.5M consensus estimate, while delivering net income of $39.2M versus a $26.4M loss last year. The company closed a $91M Zydus Lifesciences deal, boosted cash to $35M, and began global Phase 3 BATTMAN trial enrollment.
1. Financial Results
For the quarter ended March 31, 2026, Agenus generated total revenue of $33.7 million, up from $24.1 million a year earlier but below the $129.5 million analyst estimate. The company swung to net income of $39.2 million compared with a $26.4 million loss in Q1 2025.
2. Clinical Progress
In April 2026 Agenus began enrolling patients in its global Phase 3 BATTMAN trial, which is evaluating the BOT+BAL combination versus best supportive care in refractory, unresectable microsatellite stable/mismatch repair proficient metastatic colorectal cancer across sites in Canada, France, Australia and New Zealand.
3. Zydus Collaboration
A strategic transaction with Zydus Lifesciences closed in January 2026, providing $91 million in upfront capital—including $75 million in cash and a $16 million equity investment—and securing dedicated U.S. biologics manufacturing capacity for BOT+BAL development and potential commercialization.
4. Liquidity and Outlook
Agenus held $35.0 million in cash and equivalents as of March 31, up from $3.0 million at year-end 2025, with a current ratio of 0.41. Management noted that Q1 cash outflows included one-time Zydus closing costs and supply-build expenses not viewed as recurring operational charges.
